WO2014125052A1 - Composition pharmaceutique pour administration par voie orale comprenant de la fexofénadine et son procédé de préparation - Google Patents

Composition pharmaceutique pour administration par voie orale comprenant de la fexofénadine et son procédé de préparation Download PDF

Info

Publication number
WO2014125052A1
WO2014125052A1 PCT/EP2014/052869 EP2014052869W WO2014125052A1 WO 2014125052 A1 WO2014125052 A1 WO 2014125052A1 EP 2014052869 W EP2014052869 W EP 2014052869W WO 2014125052 A1 WO2014125052 A1 WO 2014125052A1
Authority
WO
WIPO (PCT)
Prior art keywords
fexofenadine
pharmaceutically acceptable
acceptable salt
water
pharmaceutical composition
Prior art date
Application number
PCT/EP2014/052869
Other languages
English (en)
Inventor
Georges Daste
Benjamin DEROUET
Marie RENOUARD
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of WO2014125052A1 publication Critical patent/WO2014125052A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to a formulation of fexofenadine or a pharmaceutically acceptable salt thereof. More particularly, it relates to a pharmaceutical composition for oral administration comprising high(methyl)pectin, glycerol, water and fexofenadine or a pharmaceutically acceptable salt thereof.
  • the present invention also concerns a process for preparing the pharmaceutical composition and the use of said pharmaceutical composition as a medicament.
  • Fexofenadine is a well-known antihistamine compound with a selective peripheral H1 -receptor antagonist activity.
  • Fexofenadine as a substance is usually used in the form of fexofenadine hydrochloride represented by formula (I) below:
  • fexofenadine hydrochloride is known from US 6,1 13,942.
  • fexofenadine hydrochloride is commercially available under the trade name ALLEGRA®.
  • ALLEGRA is a coated tablet suitable for oral administration. Because of some properties of fexofenadine hydrochloride, tablets containing so are big enough. Indeed, the total content of fexofenadine hydrochloride in a tablet cannot exceed 30% by weight (wt) of the total tablet weight. Thus, some patients, especially elderly patients and children, may have difficulty in swallowing the rather large tablet. Additionally, the administration of a tablet usually requires the ingestion of a liquid in order to facilitate the swallowing. In everyday life, patients do not have always liquids at hand. These issues can result in poor compliance or non-compliance with the treatment. Other formulations of fexofenadine have been further proposed.
  • WO 03/041683 discloses an orodispersible tablet containing fexofenadine. While orodispersible formulations can be more easily swallowed, taking them may be considered unpleasant by some patients.
  • WO 00/21510 discloses a liquid formulation of fexofenadine, suitable for nasal or ophthalmic administration. These two types of administration may be of interest in some specific local treatments, with a limited bioavailability. However, fexofenadine is highly active when orally administered. This explains why this last way of administration is usually preferred.
  • the present invention thus relates to a pharmaceutical composition for oral administration comprising:
  • wt 0-5% wt, when present, preferably 0.5-2.5% wt, of at least one other ingredient selected in the group consisting of: sugar substitutes, flavouring agents and/or colouring agents, the weight percentages being relative to the total weight of the composition, and the pH of the composition being within the range of about 2.8 to about 3.2.
  • Pectin is represented by general formula (II) below:
  • pectin which is extracted normally, more than 50% of the acid units are esterified.
  • This pectin is usually classified and known as "high methyl ester pectin” or "high(methyl)pectin”.
  • the percentage of ester groups is known as the degree of esterification (DE).
  • high(methyl)pectin has a DE from about 50 to about 80, more preferably, from about 65 to about 75.
  • High(methyl)pectin is an important ingredient of the composition. Indeed, high(methyl)pectin allows one to obtain a composition, which, once formed, can be grasped. Additionally, with high(methyl)pectin, the gelling of the composition is easily controlled, occurs rapidly, i.e. in less than 2 hours, and doesn't require heating the composition to a temperature above 90°C, thus avoiding any potential degradation of other ingredients, in particular, fexofenadine, or its pharmaceutically acceptable salt thereof.
  • glycerol is introduced as a sort of co-agent of the pectin, which allows, with the presence of water and the adjustment of the pH, the gelling of the composition. Additionally, the presence of glycerol avoids the use of sucrose in the compositions, sucrose being caloric and cariogenic.
  • One particular advantage of the pharmaceutical composition according to the invention is that said composition is sugar free.
  • water introduced into the composition is purified water according to the U.S. and E.U. pharmacopeias.
  • the composition according to the invention may comprise at least one surfactant, the presence of which is only required in some particular embodiments.
  • the presence of the surfactant may be required depending on the process for preparing the pharmaceutical composition.
  • the step (i) of mixing fexofenadine or a pharmaceutically acceptable salt thereof, the pharmaceutical excipient, glycerol and water may comprise the addition of a surfactant, depending on the particular embodiment of this step (i) (see below).
  • the surfactant is used to disperse the fexofenadine, or a pharmaceutically acceptable salt thereof, and the pharmaceutical excipient.
  • the surfactant is preferably a non-ionic surfactant.
  • the surfactant is chosen among the group consisting of: ethylene propylene oxide copolymers, such as those sold under the trademark POLOXAMER, polysorbates, such as those sold under the trademark TWEEN.
  • the surfactant is a polyoxyethylene (20) sorbitan monooleate (or polysorbate 80) such as sold under the trade name TWEEN 80.
  • Fexofenadine introduced into the composition is preferably a salt of fexofenadine, more preferably, fexofenadine hydrochloride as represented by formula (I) above.
  • Fexofenadine hydrochloride exists under three forms, depending on the degree of hydration of the salt.
  • fexofenadine hydrochloride is in form I, i.e. anhydrous.
  • composition according to the invention comprises a pharmaceutical excipient that can form a complex with the fexofenadine or its pharmaceutically acceptable salt.
  • the pharmaceutical excipient is ⁇ -cyclodextrin.
  • composition according to the invention may comprise at least one other ingredient selected in the group consisting of: sugar substitutes, flavouring agents and/or colouring agents.
  • sugar substitute it is meant a food additive that replicates the taste of sugar.
  • said sugar substitutes are artificial sweeteners such as sucralose, saccharine and/or potassium acesulfame.
  • the flavouring agents are preferably selected in the group consisting of lime, lemon, strawberry and apple.
  • colouring agents it is meant dyes, lakes and/or opacifying agents. Examples of such colouring agents are red iron oxide, yellow iron oxide, Ti0 2 , carmine E120, FD&C blue no. 1 Aluminium Lake, etc.
  • the pH of the composition must be adjusted within a range of about 2.8 to about 3.2, preferably, within the range of about 2.9 to about 3.1 .
  • Said adjustment is performed by adding an acid to the composition.
  • the acid is chosen among the group consisting of citric acid, tartaric acid, phosphoric acid and/or lactic acid, and is more preferably, citric acid.
  • the pharmaceutical composition according to the invention has a water activity of less than 0.61 .
  • the « water activity » represents the water availability (i.e. free water) which can be used by the microorganisms for their growth within the sample.
  • the water activity may be measured by methods known in the art.
  • the water activity is less than 0.60, more preferably, less than 0.59 and still more preferably less than 0.58.
  • This low water activity is of particular interest because it renders the addition of preservatives to the composition, such as parabens, unnecessary.
  • the pharmaceutical composition according to the invention forms a solid which is chewable. Moreover, for patients having few or no teeth, said solid composition can also be sucked. This pharmaceutical composition can thus be easily ingested by all patients, particularly by the elderly and the children.
  • the pharmaceutical composition may also have an agreeable appearance and a pleasant taste:
  • the taste of the composition can be modified by the addition of suitable sugar substitute(s) and flavouring agent(s), and
  • - colouring agent(s) may render the chewable composition more attractive.
  • the pharmaceutical composition according to the invention can be used as a medicament, in particular as an antihistamine and/or a bronchodilator, and is particularly suitable for the treatment of an allergy and/or urticaria. Furthermore, the pharmaceutical composition according to the invention can be used in a method of treatment of an allergy and/or urticaria, said method comprising the administration of the pharmaceutical composition of the invention to a patient.
  • the pharmaceutical composition under solid form, can be divided into units, each unit comprising a dose of fexofenadine or a pharmaceutically acceptable salt thereof.
  • a unit of 0.75g, 1 .5g and 3g can comprise respectively a dose of 30, 60 and 120mg of fexofenadine or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition according to the invention may form units, which are graspable.
  • a 1 .5g unit of the pharmaceutical composition has a hardness above 30g, preferably comprised in the range from 40g to 200g, more preferably from 50g to 150g, when measured by a texture analyser. Measurements by a texture analyser are known in the art. An example of such a measurement is more specifically described in the example.
  • the present invention further relates to a process for preparing a pharmaceutical composition according to the invention, comprising the following steps: i) Mixing fexofenadine or a pharmaceutically acceptable salt thereof, the pharmaceutical excipient, glycerol and water,
  • step (i) Heating the resulting mixture of step (ii) to a temperature ranging from about 60°C to about 90°C, preferably at a temperature of about 70°C, iv) Adjusting the pH with an acid,
  • step (i) of the process is to solubilize fexofenadine, or a pharmaceutically acceptable salt thereof, by complexing it with the pharmaceutical excipient, and to disperse said resulting complex in glycerol and water.
  • this solubilization and dispersion can be performed according to different embodiments.
  • step (i) is performed as followed: a) Mixing fexofenadine, or a pharmaceutically acceptable salt thereof, and the pharmaceutical excipient with water,
  • step (a) Adding glycerol and the surfactant to the resulting mixing of step (a). More particularly, step (a) comprises several sub-steps:
  • the pharmaceutical excipient is first mixed with a part of water in order to obtain a mixing having a pasty consistency
  • a part of fexofenadine or a pharmaceutically acceptable salt thereof is added to the mixture having a pasty consistency followed by another part of water;
  • a surfactant is added to disperse the different ingredients.
  • said dispersion is notably improved by the progressive addition of water and fexofenadine, or a pharmaceutically acceptable salt thereof.
  • the rest of water is added after a contact time of at least 45 min, preferably, at least 1 h.
  • step (a) may comprise the following sub-steps:
  • the pharmaceutical excipient is first mixed with 50% (half) of the water in order to obtain a mixture having a pasty consistency
  • the percentages are relative to the total content of each ingredient.
  • step (i) is performed as follows:
  • step (II) the fexofenadine, or a pharmaceutically acceptable salt thereof, and the pharmaceutical excipient are added to the mixture of step (I) in a powder form, said powder comprising the fexofenadine or a pharmaceutically acceptable salt thereof complexed with the pharmaceutical excipient.
  • Such a powder comprising the fexofenadine, or a pharmaceutically acceptable salt thereof, complexed with the pharmaceutical excipient can be prepared as follows:
  • the pharmaceutical excipient is first mixed with a quantity of water (the quantity representing 10 to 20% of the total weight of both components : fexofenadine or a pharmaceutically acceptable salt thereof and the pharmaceutical excipient), in order to obtain a mixture having a pasty consistency;
  • the resulting paste is then dried at about 60°C during at least 2 hours in order to remove the water.
  • the dried product is finally ground in order to obtain a powder.
  • step (ii) is performed after heating the mixture of step (i) to a temperature within the range of about 35°C to 45°C, preferably at about 40°C.
  • the pH is adjusted with citric acid, tartaric acid, phosphoric acid and/or lactic acid, and more preferably, with citric acid.
  • the forming step is performed by pouring the pharmaceutical composition into moulds.
  • the moulds may be further lined up to form a blister pack, which may then be thermally sealed.
  • the forming step is performed by deposition of a drop of the pharmaceutical composition on a cooled belt. The drops solidify and cool as they travel along with the belt. The solidified units are then discharged at the end of the belt and collected.
  • the cooled belt may be made of steel or another suitable material.
  • Figure 1 which is a photo of a mould filled with the composition according to the invention
  • Figure 2 which is a diagram of the mould used to prepare the units of composition in example 1 .
  • a pharmaceutical composition according to the invention was prepared with the following ingredients:
  • the aim of the first steps of the process is to solubilize and disperse the fexofenadine: 67.6g of ⁇ -cyclodextrin is mixed with 44g of water to form a pasty mixture. Then, 12g of fexofenadine is added to the mixture, followed by 31 g of water, the addition of the water having the purpose of avoiding the hardening of the mixture. Finally, the rest of fexofenadine is added, followed by the rest of water.
  • glycerol and 0.8g of surfactant are then added to the mixture and mixed.
  • the mixture is heated at 40°C.
  • 8g of high(methyl)pectin is added to the mixture.
  • 2g of sucralose and 2g of lime flavour are added to the mixture, which is then heated to a temperature of 70°C.
  • the pH is adjusted with a solution of citric acid 10% w/w.
  • the resulting mixture is the pharmaceutical composition according to the invention.
  • Said composition is then poured into plastic or metal-laminated moulds.
  • An example of blister pack is illustrated in Figure 2.
  • the blister pack 1 comprises two parallel rows of cavities 2 and is reinforced by a central rib 3. Each cavity is cup-shaped.
  • the maximum diameter of the cup (at the surface of the blister pack 1 ) is about 20 mm and its depth is about 6.5 mm.
  • Each cavity is filled with 1.5g (corresponding to a dose of 60mg of fexofenadine hydrochloride) of the pharmaceutical composition 4, which is liquid.
  • the blister pack is then thermally sealed with a foil cover sheet, and the pharmaceutical composition is cooled until the composition gels.
  • the pharmaceutical composition according to the invention can be easily turned out of the moulds to form a moulded unit and is easily grasped, as shown in figure 1 .
  • the pharmaceutical composition according to the invention does not require the use of any preservatives.
  • the addition of parabens can be avoided. This feature can be evidenced by measuring the water activity of the pharmaceutical composition according to the invention.
  • the water activity is measured by using a Rotronic Hygrolab device. This measurement is not carried out on an entire moulded unit, but on a sample portion of said unit, the sample having the following dimensions: 20mm in diameter (x) 2-3 mm in thickness. This portion is sliced from the moulded unit. The sample is then introduced into the measuring cell. After a short equilibrium time, the value can be read.
  • the water activity as measured is: 0.58. This result is below a water activity of 0.61 , which represents the upper limit, above which a preservative is required. 4. Hardness
  • the moulded units are easily grasped.
  • the hardness of said units has been measured with a texture analyser.
  • the texture analyser is a TA.XT.plus Texture Analyser, from Stable Micro Systems® equipped with a 6 mm diameter cylinder probe with a 5kg load cell.
  • Trigger type Auto - 5.0g
  • the measurement is performed on a sample constituted by a moulded unit.
  • This moulded unit is positioned so as the surface which was in contact with the cup of the blister pack is facing upwards. Once the probe has touched said surface of the sample, it penetrates it until a depth of 1 mm is reached. At this depth, the load is measured and this value represents the hardness of the sample. To assess the reproductibility of the measurement, 10 samples are tested.
  • the hardness measured is comprised in the range from 50 to 100g. It has been determined that a unit having a hardness below 30g is not graspable. This confirms that the moulded units of the pharmaceutical composition according to the invention are graspable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques destinées à être administrées par voie orale, lesdites compositions comprenant de la pectine hautement méthylée, du glycérol, de l'eau et de la fexofénadine, ou un sel pharmaceutiquement acceptable associé. L'invention concerne également les utilisations desdites compositions en tant que médicament ainsi que le procédé de préparation desdites compositions.
PCT/EP2014/052869 2013-02-14 2014-02-14 Composition pharmaceutique pour administration par voie orale comprenant de la fexofénadine et son procédé de préparation WO2014125052A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305173 2013-02-14
EP13305173.0 2013-02-14

Publications (1)

Publication Number Publication Date
WO2014125052A1 true WO2014125052A1 (fr) 2014-08-21

Family

ID=47739181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/052869 WO2014125052A1 (fr) 2013-02-14 2014-02-14 Composition pharmaceutique pour administration par voie orale comprenant de la fexofénadine et son procédé de préparation

Country Status (4)

Country Link
AR (1) AR094761A1 (fr)
TW (1) TW201440808A (fr)
UY (1) UY35329A (fr)
WO (1) WO2014125052A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740193A4 (fr) * 2018-01-15 2022-03-02 Seattle Gummy Company Compositions anti-histaminiques semi-solides et leurs procédés de fabrication et d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021510A2 (fr) 1998-10-13 2000-04-20 West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. Nouvelles formulations de fexofenadine
US6113942A (en) 1995-02-28 2000-09-05 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
WO2003041683A2 (fr) 2001-11-16 2003-05-22 Ethypharm Comprimes orodispersibles contenant du fexofenadine
WO2007017905A1 (fr) * 2005-08-05 2007-02-15 Lupin Limited Compositions pharmaceutiques de fexofenadine sous forme de suspension et destinees a une administration par voie orale
WO2013015545A1 (fr) * 2011-07-28 2013-01-31 Kwang Dong Pharm. Co., Ltd. Composition pour film pelliculaire consommable et préparation pharmaceutique pour film pelliculaire consommable contenant des médicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113942A (en) 1995-02-28 2000-09-05 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
WO2000021510A2 (fr) 1998-10-13 2000-04-20 West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. Nouvelles formulations de fexofenadine
WO2003041683A2 (fr) 2001-11-16 2003-05-22 Ethypharm Comprimes orodispersibles contenant du fexofenadine
WO2007017905A1 (fr) * 2005-08-05 2007-02-15 Lupin Limited Compositions pharmaceutiques de fexofenadine sous forme de suspension et destinees a une administration par voie orale
WO2013015545A1 (fr) * 2011-07-28 2013-01-31 Kwang Dong Pharm. Co., Ltd. Composition pour film pelliculaire consommable et préparation pharmaceutique pour film pelliculaire consommable contenant des médicaments

Also Published As

Publication number Publication date
AR094761A1 (es) 2015-08-26
TW201440808A (zh) 2014-11-01
UY35329A (es) 2014-09-30

Similar Documents

Publication Publication Date Title
Arya et al. Fast dissolving oral films: an innovative drug delivery system and dosage form
Panigrahi et al. A review on fast dissolving tablets
Chandrasekhar et al. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets
JP5537943B2 (ja) 速崩壊性固形製剤
CA2864322C (fr) Film a haute teneur et a dissolution rapide a gout amer masque comprenant du sildenafil comme principe actif
EP1765299B1 (fr) Procede servant a formuler des formes de dosage se dispersant rapidement comprenant au moins une gelatine de poisson selectionnee en fonction du poids moleculaire de cette derniere
Juluru Fast dissolving oral films: A review
EA019614B1 (ru) Усовершенствованная фармацевтическая композиция, содержащая антагонист дигидропиридинкальциевого канала, и способ ее получения
US10624845B2 (en) Quick dissolving diphenhydramine oral dosage form
EP2956011B1 (fr) Composition à mâcher pour administration orale et son procédé de préparation
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
WO2014125052A1 (fr) Composition pharmaceutique pour administration par voie orale comprenant de la fexofénadine et son procédé de préparation
AU2012241189A1 (en) Fast Dissolving Solid Dosage Form
Patel et al. A NOVEL APPROACH FOR BUCCAL DRUG DELIVERY SYSTEM-BUCCAL FILM.
Zulkifli et al. The effect of disintegrants on the physical properties of a cocoa butter based fast melt tablet developed by a fusion moulding method
US20170209369A1 (en) Semi-solid chewable dosage form for over-the-counter medications and method for producing same
WO2011115599A2 (fr) Formulations de comprimé délitant par voie orale de donépézil et procédé pour préparer celui-ci
Patange et al. A Review on Mouth Dissolving Film
Sairam et al. DESIGN & DEVELOPMENT OF FAST DISSOLVING ORAL FILMS OF KETOPROFEN
Mannur et al. Formulation and Evaluation of Ranitidine Hydrochloride Mouth Dissolving Tablet by Effervescent Formulation Technique.
JP2023532121A (ja) ロゼンジ
JPH10130140A (ja) グミ製剤の製造方法
Solan INTERNATIONALE PHARMACEUTICA SCIENCIA
EZETAMIBE et al. PHARMACEUTICAL SCIENCES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14704350

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14704350

Country of ref document: EP

Kind code of ref document: A1